Protective effect of thymoquinone against doxorubicin-induced cardiotoxicity in rats: A possible mechanism of protection

被引:233
作者
Nagi, MN [1 ]
Mansour, MA [1 ]
机构
[1] King Saud Univ, Coll Pharm, Dept Pharmacol, Riyadh 11451, Saudi Arabia
关键词
thymoquinone; lactate dehydrogenase; creatine phosphokinase; cardiotoxicity; doxorubicin;
D O I
10.1006/phrs.1999.0585
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Administration of thymoquinone (10 mg kg(-1) day(-1), p.o.) with drinking water starting 5 days before a single injection of doxorubicin (15 mg kg(-1) i.p.) and continuing during the experimental period ameliorated the doxorubicin-induced cardiotoxicity in rats. This protection was evidenced from the significant reduction in serum enzymes: lactate dehydrogenase elevated level, 24 h and creatine phosphokinase elevated levels, 24 h and 48 h after doxorubicin administration. The cardiotoxicity of doxorubicin has been suggested to result from the generation of superoxide free-radical. The protective action of thymoquinone was examined against superoxide anion radical either generated photochemically, biochemically or derived from calcium ionophore (A23187) stimulated polymorphonuclear leukocytes. The results indicate that thymoquinone is a potent superoxide radical scavenger, scavenging power being as effective as superoxide dismutase against superoxide. In addition thy moquinone has an inhibitory effect on lipid peroxidation induced by Fe3+/ascorbate using rat heart homogenate. The superoxide scavenging and anti-lipid peroxidation may explain, in part, the protective effect of thymoquinone against doxorubicin-induced cardiotoxicity. (C) 2000 Academic Press.
引用
收藏
页码:283 / 289
页数:7
相关论文
共 28 条
  • [1] Al-Gharably NM, 1997, RES COMMUN PHARM TOX, V2, P41
  • [2] Al-Shabanah OA, 1998, J EXP CLIN CANC RES, V17, P193
  • [3] Thymoquinone ameliorates the nephrotoxicity induced by cisplatin in rodents and potentiates its antitumor activity
    Badary, OA
    Nagi, MN
    Al-Shabanah, OA
    Al-Sawaf, HA
    Al-Sohaibani, MO
    Al-Bekairi, AM
    [J]. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1997, 75 (12) : 1356 - 1361
  • [4] Badary OA, 1998, DRUG DEVELOP RES, V44, P56, DOI 10.1002/(SICI)1098-2299(199806/07)44:2/3&lt
  • [5] 56::AID-DDR2&gt
  • [6] 3.0.CO
  • [7] 2-9
  • [8] SUPEROXIDE DISMUTASE - IMPROVED ASSAYS AND AN ASSAY APPLICABLE TO ACRYLAMIDE GELS
    BEAUCHAM.C
    FRIDOVIC.I
    [J]. ANALYTICAL BIOCHEMISTRY, 1971, 44 (01) : 276 - &
  • [9] ANTHRACYCLINE ANTIBIOTICS IN CANCER-THERAPY - FOCUS ON DRUG-RESISTANCE
    BOOSER, DJ
    HORTOBAGYI, GN
    [J]. DRUGS, 1994, 47 (02) : 223 - 258
  • [10] BUHL SN, 1978, CLIN CHEM, V24, P828